A 3-way, Crossover, Randomized, Open-label Study in Healthy Subjects Comparing the Bioavailability of Belumosudil (KD025) Tablets in Fed and Fasted States and Relative Bioavailability of Tablets and Capsules in the Fed State
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Belumosudil (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Kadmon Corporation
- 13 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 Sep 2015 New trial record